Business Pundit (Free subscription) | 3 hours ago
Someone needs to make a movie about Carl Icahn. The all-star corporate raider is at it again. Icahn, who chairs the notorious pharmaceutical company ImClone’s board, has accepted a $70/share buyout of the company. From Reuters: Eli Lilly and Co has agreed to acquire ImClone Systems Inc for $6.5 billion, potentially bringing to a close one [...]
Market Watch (Free subscription) | 3 hours ago
NEW YORK (MarketWatch) - Billionaire investor Carl Icahn said Monday that he is launching a lobbying group named United Shareholders to push legislators to pass more investor-friendly laws.
24/7 Wall St. (Free subscription) | 4 hours ago
Carl Icahn appears to have won a blue ribbon for ImClone Systems (NASDAQ: IMCL) shareholders. The biotech stock is trading up on a very weak trading day after... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Forbes (Free subscription) | 2 hours ago
Carl Icahn sells ImClone to Eli Lilly for $7 a share more than Bristol was offering.
Bio-IT World | Top Headlines (Free subscription) | 30/09/2008
Bristol-Myers Presses ImClone; Icahn Fires Back | Analysts were split, though, on whether the world's No. 14 drugmaker can force ImClone Chairman Carl Icahn to capitulate and accept an increased offer from Bristol-Myers, which already owns 17 percent of ImClone. 0 CommentsAdd Comment Text Only 2000 character limit Page 1 of 1
Law Blog - WSJ.com (Free subscription) | 6 hours ago
Eli Lilly has inked a $6.5 billion deal to acquire ImClone, a deal which has the support of Carl Icahn.
LA Times (Free subscription) | 4 hours ago
ImClone said its chairman, Carl Icahn, who owns about 14 percent of ImClone stock, has agreed to vote in favor of the Lilly deal.In a press release, Icahn said the move "vindicated" his opposition to a 2006 buyout offer that was worth $36 per share. The billionaire investor became ImClone's chairman in late October of that year after replacing several of the company's directors,...
Seattle Times (Free subscription) | 4 hours ago
... Bristol-Myers Squibb had no immediate comment on the Lilly offer Monday.ImClone said its chairman, Carl Icahn, who owns about 14 percent of ImClone stock, has agreed to vote in favor of the Lilly deal.In a press release, Icahn said the move "vindicated" his opposition to a 2006 buyout offer that was worth $36 per share. The billionaire investor became ImClone's chairman in...
USA Today (Free subscription) | 5 hours ago
... Bristol-Myers Squibb had no immediate comment on the Lilly offer Monday.ImClone said its chairman, Carl Icahn, who owns about 14% of ImClone stock, has agreed to vote in favor of the Lilly deal.In a press release, Icahn said the move "vindicated" his opposition to a 2006 buyout offer that was worth $36 a share. The billionaire investor became ImClone's chairman in late October...
MSNBC.com (Free subscription) | 5 hours ago
... Bristol-Myers Squibb had no immediate comment on the Lilly offer Monday.ImClone said its chairman, Carl Icahn, who owns about 14 percent of ImClone stock, has agreed to vote in favor of the Lilly deal.In a press release, Icahn said the move “vindicated” his opposition to a 2006 buyout offer that was worth $36 per share. The billionaire investor became ImClone’s chairman in...
The Street (Free subscription) | 11 hours ago
... at $64.96. It was reported last week that Eli Lilly was ImClone's mystery bidder. ImClone Chairman Carl Icahn said the mystery suitor made a proposal not subject to financing or further due diligence. Negotiations were reportedly under way last week and the company requested that ImClone not reveal the bidder's name until negotiations were complete.
Reuters UK (Free subscription) | 5 hours ago
It also represents a satisfying victory for Carl Icahn, the billionaire investor and chairman of ImClone's board, who took control of ImClone in 2006 at a time many investors had written the company off and almost no analysts were recommending the stock.
Market Watch (Free subscription) | 3 hours ago
... ImClone's only marketed product, the cancer therapy Erbitux, in North America. ImClone Chairman Carl Icahn had rejected both bids from Bristol-Myers, calling the $62-a-share proposal "absurd." Shares of partners Genentech Inc. DNAand OSI Pharmaceuticals OSIPwere both lower after they reported disappointing results from a Phase III clinical trial that tested Genentech's leading oncology...
Superior Investor (Free subscription) | 4 hours ago
... from Friday’s closing price. Bristol-Myers Squibb currently owns 17% of ImClone and investor Carl Icahn owns 16%. “We think very highly of ImClone’s ground-breaking work in oncology, particularly its success with ERBITUX(R), a blockbuster targeted cancer therapy, and its ability to advance promising biotech molecules in its pipeline,” said John C. Lechleiter, Ph.D., Lilly’s president...
Postman Patel (Free subscription) | 4 hours ago
... Waksal and style guru / part time cook Martha Stewart tasting poridge in unfamiliar circumstances.Carl Icahn, the billionaire investor and chairman of ImClone's board, who got control in 2006 will no doubt be pleased with the result and returns on his investment (14%) and has approved Lilly's offer for his Lilly is seeing big competition to their biggest drugs, including schizophrenia...
